

New drug shows improved progression-free survival for patients with advanced metastatic midgut neuroendocrine tumors

January 12 2017

A new therapy in development for the treatment of midgut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, shows improved progression-free survival and response rates for patients with advanced disease. Results of the international phase 3 clinical trial of lutetium-177 (¹⁷⁷Lu)-Dotatate compared to high-dose octreotide LAR were published in the Jan. 12 issue of the *New England Journal of Medicine*.

"Patients diagnosed with midgut neuroendocrine tumors often have advanced disease that has spread to other sites. Treatment options are limited. ¹⁷⁷Lu-Dotatate is an effective option to delay tumor progression for patients with this disease," says Jonathan R. Strosberg, head of the Neuroendocrine Tumor Program at Moffitt Cancer Center. "There is also preliminary evidence of survival benefit that requires confirmation on final survival analysis, expected in several years."

Standard [treatment](#) for midgut neuroendocrine tumors is hormonal therapy using a somatostatin analog that blocks the growth of tumor cells and reduces the production of hormones that cause symptoms such as flushing and diarrhea. If a patient's tumors progress on somatostatin analog therapy, there are currently not many other treatment options.

Moffitt is one of 41 cancer centers worldwide to investigate a novel therapy, ¹⁷⁷Lu-Dotatate. The drug consists of a radioactive molecule

attached to a somatostatin analog, allowing for radiation to be directly targeted to somatostatin receptor expressing tumors. Patients with metastatic or locally advanced midgut neuroendocrine tumors that had disease progression during prior treatment with octreotide, a somatostatin analog, were enrolled in the trial.

Trial results showed that patients who were treated with ¹⁷⁷Lu-Dotatate and octreotide had better outcomes than patients who were treated with high-dose octreotide alone. The 20-month progression-free survival rate was 65.2 percent in the ¹⁷⁷Lu-Dotatate group and 10.8 percent in the control group. ¹⁷⁷Lu-Dotatate-treated patients had a 79 percent lower risk of disease progression or death than the control patients over the follow-up period. Additionally, more patients treated with ¹⁷⁷Lu-Dotatate achieved a radiographic response than patients in the control group (18 percent versus 3 percent).

"This is notable given that response rates above 5 percent have not been observed in large randomized clinical trials of other systemic therapies in this patient population," said Dr. Strosberg. "The clinically meaningful and statistically significant improvement in progression-free survival and response rates achieved with treatment of ¹⁷⁷Lu-Dotatate when compared to high dose octreotide supports its use in the treatment of neuroendocrine tumor patients. As a clinician treating many patients with this condition, these results bring hope for our ability to improve lives."

The trial data showed that ¹⁷⁷Lu-Dotatate-treated patients experienced more adverse events than control patients (86 percent versus 31 percent), but the toxicities were manageable and reversible. The most common adverse events with ¹⁷⁷Lu-Dotatate were nausea and vomiting, but this was attributed to amino acid infusions that were given to the patients to relieve potential kidney toxicity. Toxicities that occurred more in the ¹⁷⁷Lu-Dotatate-treated [patients](#) included thrombocytopenia, anemia,

lymphopenia, and leukopenia.

More information: Jonathan Strosberg et al, Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors, *New England Journal of Medicine* (2017). [DOI: 10.1056/NEJMoa1607427](https://doi.org/10.1056/NEJMoa1607427)

Provided by H. Lee Moffitt Cancer Center & Research Institute

Citation: New drug shows improved progression-free survival for patients with advanced metastatic midgut neuroendocrine tumors (2017, January 12) retrieved 28 April 2024 from <https://medicalxpress.com/news/2017-01-drug-progression-free-survival-patients-advanced.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.